Amlodipine Besylate Market: Current Analysis and Forecast (2023-2030)
Emphasis on Dosage Type (2.5 mg, 5 mg, and 10 mg); Application (High Blood Pressure and Heart Diseases); and Region/Country
The Global Amlodipine Besylate Market was valued at USD 350 million in 2022, growing at a CAGR of 4.5% during the forecast period from 2023 – 2030. Amlodipine besylate services mainly gained prominence due to the increased cases of uncontrolled high blood pressure globally. For instance, in July 2023, the Centers for Disease Control and Prevention (CDC) reported only about 1 in 4 adults with hypertension have their hypertension under control. In addition to this, investments in cardiovascular departments as well as government awareness programs regarding heart diseases have increased significantly in recent years, which are the key factors that are creating opportunities for the market. Many other factors were identified that helped in propelling the market in the forecast period such as the surge in awareness programs regarding cardiovascular disorders, the increasing smoking population, rising alcoholism culture are also driving the growth of the market. For instance, in November 2021, the Support Network-Ghana (SASNET-GHANA) celebrated World Heart Day on 29, September 2021 by raising population awareness of cardiovascular diseases (CVD) through the usage of traditional and social media.
Alkem Laboratories Ltd.; Mylan Inc.; Dr. Reddy’s Laboratories Ltd.; Macleods Pharmaceuticals Ltd.; Lupin; Aurobindo Pharma; Pfizer Inc.; Cipla Inc.; Sun Pharmaceutical Industries Ltd.; Wockhardt are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
“Amongst dosage type, 5 mg category to witness higher CAGR during the forecast period”
Based on dosage type, the market is segmented into 2.5 mg, 5 mg, and 10 mg. The 5 mg segment is expected to grow with a high CAGR during the forecast period as there is a growing adoption of medicine in the form of tablets. Evidently, tablets are reported to be the most consumed solid dosage forms among all medication forms, because of their highly effective composition, and ease in consumption. For instance, according to the Journal of the American Heart Association in January 2022, CADUET tablets, oval and film-coated white, made with combinations of atorvastatin, an HMG CoA-reductase inhibitor with 5 mg amlodipine besylate, a calcium channel blocker was found to be effective in patients with hypertension) and high cholesterol triglyceride levels. Thus, amongst dosage types, the 5 mg category is expected to witness higher CAGR during the forecast period.
“Amongst application, heart diseases held a significant share in the market in 2022”
Based on application, the market is categorized into high blood pressure and heart diseases. The heart disease segment is dominating the market in 2022 owing to the rising sedentary lifestyle, inappropriate eating habits, and rising geriatric population. Additionally, there have been increased incidences of genetic disorders globally which is a driving factor for this segment. For instance, according to a report published in 2022, by the American Heart Association, a US-based organization, the age-adjusted prevalence rate of cardiovascular diseases was 7354.1 per 100,000 people in 2020. Thus, the heart disease segment held a significant share of the market in the year 2022.
“Amongst regions, North America held higher CAGR during the forecast period”
For a better understanding of the market adoption of amlodipine besylate, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR during the forecast period. Several factors such as a surge in the geriatric population in the region, development of a wide range of therapeutics with amlodipine besylate, and enhanced accessibility of pharmaceutical products are driving the market’s growth during the forecast period. Further, the increase in incidences of cardiovascular diseases, the presence of key generic pharmaceutical companies in the region, and the surge in government initiatives and special communities are also having a positive impact on the market’s growth. There have been significant improvisations and enhancements in amlodipine besylate in the region. For example, in June 2022, US-based CMP Pharma launched Norliqva, an amlodipine liquid solution used to treat high blood pressure in people 6 years of age and older. The unique feature of Norliqva is that it is the first and only oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker. Norliqva is a privilege for those patients who face difficulty in swallowing tablets. Hence, North America is supposed to witness a higher CAGR during the forecast period.
Q1: What is the current market size and growth potential of the amlodipine besylate market?
Ans: The amlodipine besylate market was valued at USD 350 Million in 2022 and is expected to grow a CAGR of 4.5% during the forecast period (2023-2030).
Q2: What are the driving factors for the growth of the amlodipine besylate market?
Increased consumption of alcohol and tobacco, the surge in awareness programs regarding cardiovascular diseases, and rising investments in cardiovascular departments are the driving factors for the growth of the amlodipine besylate market.
Q3: Which segment has the largest share of the amlodipine besylate market by dosage type?
Ans: The 10 mg segment has the largest share of the amlodipine besylate market by dosage type.
Q4: What are the emerging technologies and trends in the amlodipine besylate market?
Ans: The combination of drugs with amlodipine besylate, and the cure of anal fissures using amlodipine besylate are the emerging technologies and trends in the amlodipine besylate market.
Q5: Which region will dominate the amlodipine besylate market?
Ans: North America is expected to dominate the market during the forecast period.
Q6: Who are the key players operating in the amlodipine besylate market?
Ans: Alkem Laboratories Ltd.; Mylan Inc.; Dr. Reddy’s Laboratories Ltd.; Macleods Pharmaceuticals Ltd.; Lupin; Aurobindo Pharma; Pfizer Inc.; Cipla Inc.; Sun Pharmaceutical Industries Ltd.; Wockhardt are the key players operating in the amlodipine besylate market.
Amlodipine Besylate Market Report Coverage
Reasons to buy this report:
- The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
- The report presents a quick review of overall industry performance at one glance.
- The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
- Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
- The study comprehensively covers the market across different segments.
- Deep dive regional level analysis of the industry.
Customization Options:
The global amlodipine besylate market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Amlodipine Besylate Market Analysis (2023-2030)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global amlodipine besylate market were the three major steps undertaken to create and analyze the adoption of amlodipine besylate in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global amlodipine besylate market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the amlodipine besylate market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the amlodipine besylate market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as dosage type, application, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the amlodipine besylate market. Further, we conducted factor analysis using dependent and independent variables such as dosage type, application, and regions of amlodipine besylate. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the amlodipine besylate market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global amlodipine besylate market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 00for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
- The industry’s market size, in terms of revenue (USD) and the adoption rate of the amlodipine besylate market across the major markets domestically
- All percentage shares, splits, and breakdowns of market segments and sub-segments
- Key players in the global amlodipine besylate market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global amlodipine besylate market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of dosage type, application, and regions in the global amlodipine besylate market.
The main objective of the Global Amlodipine Besylate Market Study
The current & future market trends of the global amlodipine besylate market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
- Analyze the current and forecast market size of the amlodipine besylate market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
- Segments in the study include areas of dosage type, application, and regions
- Define and analyze the regulatory framework for the amlodipine besylate industry.
- Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
- Analyze the current and forecast market size of the amlodipine besylate market for the major region.
- Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World.
- Company profiles of the amlodipine besylate market and the growth strategies adopted by the market players to sustain in the fast-growing market
- Deep dive regional level analysis of the industry
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
